nitazoxanide has been researched along with fingolimod hydrochloride in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Butler, E; Butzkueven, H; Buzzard, K; Eichau, S; Girard, M; Hodgkinson, S; Jokubaitis, V; Kalincik, T; Lechner-Scott, J; Monif, M; Oh, J; Prevost, J; Skibina, O; van der Walt, A; Van Pesch, V; Zhong, M | 1 |
| Altieri, M; Bisecco, A; Boffa, L; Capuano, R; Cavalla, P; Cocco, E; Cordioli, C; De Luca, G; Di Gregorio, M; Fantozzi, R; Gajofatto, A; Gallo, A; Gasperini, C; Guaschino, C; Lorefice, L; Nociti, V; Paolicelli, D; Pinardi, F; Prosperini, L; Radaelli, M; Ragonese, P; Solaro, C; Torri Clerici, V; Tortorella, C | 1 |
2 other study(ies) available for nitazoxanide and fingolimod hydrochloride
| Article | Year |
|---|---|
Prediction of relapse activity when switching to cladribine for multiple sclerosis.
Topics: Chronic Disease; Cladribine; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence | 2023 |
Symptomatic COVID-19 course and outcomes after three mRNA vaccine doses in multiple sclerosis patients treated with high-efficacy DMTs.
Topics: COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; mRNA Vaccines; Multiple Sclerosis; Natalizumab; RNA, Messenger; SARS-CoV-2 | 2023 |